TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01549782

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inulin and Fructo-oligosaccharide
Description: 6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrine
Description: 6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
Study: NCT02755623

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Description: Participants are sequentially randomly assigned to either 20 active rTMS sessions or 20 sham rTMS sessions that were applied over the left temporoparietal junction. Treatments are administered daily, over a period of two weeks.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive Transcranial Magnetic Stimulation (rTMS)
Study: NCT02748837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERY974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERY974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERY974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ERY974
Study: NCT04890678

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 22 residentsat risk for PU development
Description: mattress in bed~The presence of PUs will be evaluated using the European Pressure Ulcer Advisory Panel (EPUAP) classification system (NPUAP, 2014) and the presence of incontinence- associated dermatitis (IAD) will be categorized using the Ghent Global IAD Categorisation Tool (GLOBIAD). For each participant, the Patient Repositioning Tool Ghent (PROTECT) will be used to individually recommend the frequency of skin observations and the frequency of repositioning.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 18 residents at least one PU category III-IV in the sacral area
Description: mattress in bed The presence of PUs will be evaluated using the European Pressure Ulcer Advisory Panel (EPUAP) classification system (NPUAP, 2014) and the presence of incontinence- associated dermatitis (IAD) will be categorized using the Ghent Global IAD Categorisation Tool (GLOBIAD). For each participant, the Patient Repositioning Tool Ghent (PROTECT) will be used to individually recommend the frequency of skin observations and the frequency of repositioning.~In the group of participants with a PU category III or IV, the Pressure Ulcer Scale for Healing Tool (PUSH) will be used to assess and measure change in PU status. The score on the PUSH-tool is defined by the surface area of the PU (length x width), the amount of exudate and the type of tissue in the wound bed.
Study: NCT03690141

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eFT508
Description: This Phase 2 study examines the efficacy, safety, tolerability, and PK of tomivosertib (eFT508) in advanced CRPC patients who have documented PSA progression on treatment with apalutamide and/or abiraterone and/or enzalutamide and for whom no suitable curative therapy exists.
Study: NCT00770237

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cues
Description: In the smoking cue condition, a pack of the participants preferred brand of cigarettes, a lighter, and an ashtray will be under the tray cover. In the neutral cue condition, a pack of unsharpened pencils, a pencil sharpener, and a small notepad will be under the cover. When instructed, the participant will lift the cover on the tray. In the smoking cue condition, participants will take one cigarette out of the pack, light it without puffing, hold it for 1 minute, extinguish the cigarette, and replace the cover on the tray.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neutral Cues
Description: In the neutral cue condition, participants will take one pencil out of the pack, sharpen it, hold it for 1 minute as if to write on the notepad, and then replace the cover. Participants will complete the VAS during cue exposure and the TCQ-SF, VAS, and mood form immediately and 15 minutes after cue presentation; physiological measures will be recorded continuously.
Study: NCT00041067

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Study: NCT01266525

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR110894
Description: Pharmaceutical form: Capsule~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR110894
Description: Pharmaceutical form: Capsule~Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR110894
Description: Pharmaceutical form: Capsule~Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo (for SAR110894)
Description: Pharmaceutical form: Capsule~Route of administration: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Donepezil
Description: 5 mg or 10 mg once daily continued as taken before inclusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5 mg or 10 mg once daily continued as taken before inclusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5 mg or 10 mg once daily continued as taken before inclusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: 5 mg or 10 mg once daily continued as taken before inclusion
Study: NCT01126151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent handbook
Description: parent handbook

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent handbook
Description: parent handbook

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: parent handbook
Description: parent handbook
Study: NCT04538612

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: measure capillary refill time
Description: Each time, capillary refill time will be evaluated three times consecutively by clinical method applying a firm pressure with the finger during 15s, then brutally releasing it, and estimating time of skin recoloration with a chronometer and by DiCART TM device~Three vascular occlusion tests will be successively performed with a cuff during less than 10 minutes:~* Arterial vascular occlusion test (50mmHg above systolic arterial pressure of the healthy volunteers),~* Veinous vascular occlusion test (30mmHg),~* Control test without vascular occlusion test. Capillary refill time measurements will be repeated just before, during and just after vascular occlusion tests.~Randomization determine the order of the vascular occlusion tests. Investigators performing capillary refill time evaluation will be blinded from it. Vascular occlusion tests will be alternatively performed by one and the other limb. The whole protocol will be performed at the upper and then at the lower limb.
Study: NCT00141323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lasofoxifene
Description: 0.5 mg once per day, orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lasofoxifene
Description: 0.25 mg once per day, orally
Study: NCT04258527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemigatinib
Description: Pemigatinib will be self-administered as at 13.5mg a QD oral treatment on a 2-week-on therapy and 1-week-off therapy schedule.
Study: NCT04646512

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Taurine group and exercise and placebo group and exercise
Description: Both groups supplemented with taurine and / or placebo will perform physical training.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Taurine group and exercise and placebo group and exercise
Description: Both groups supplemented with taurine and / or placebo will perform physical training.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical training with Deep Water Running
Description: There will be a physical training for eight weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical training with Deep Water Running
Description: There will be a physical training for eight weeks.
Study: NCT04239521

Intervention type: OTHER
Intervention: Exposure of interest (studies 2 & 3).
Description: Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder Atopic conditions consist of Atopic dermatitis, allergic rhinitis, asthma Autoimmune conditions consist of Crohn's disease, ulcerative colitis, Coeliac disease, Pernicious anaemia, Type 1 diabetes, Hashimoto's thyroiditis, Grave's disease, Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Systemic lupus erythematosus, polymyalgia rheumatica, Sjögren's syndrome, Psoriasis, vitiligo, Multiple sclerosis

Intervention type: OTHER
Intervention: Exposure of interest (studies 2 & 3).
Description: Common mental health conditions consist of depressive episodes, recurrent depressive disorder and anxiety disorder Atopic conditions consist of Atopic dermatitis, allergic rhinitis, asthma Autoimmune conditions consist of Crohn's disease, ulcerative colitis, Coeliac disease, Pernicious anaemia, Type 1 diabetes, Hashimoto's thyroiditis, Grave's disease, Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Systemic lupus erythematosus, polymyalgia rheumatica, Sjögren's syndrome, Psoriasis, vitiligo, Multiple sclerosis
Study: NCT01463384

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Minocycline
Description: 50mg, twice daily for 6 months.
Study: NCT00874666

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: crushed garlic clove
Description: 1 gram crushed garlic in gelatin capsules, one dose once every 2-16 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: garlic powder tablet
Description: tablets, dose to contain 1 gram of garlic powder, consume one dose once every two weeks for up to 52 weeks
Study: NCT02379481

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NS 550mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: NS 1100mg

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT00635726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate intravenous (IV) 30 mgr/m2 on day 1 every 2 weeks for 6 courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine IV 3 mgr/m2 on day 1 every 2 weeks for 6 courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin IV 30 mgr/m2 on day 2 every 2 weeks for 6 courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin IV 70 mgr/m2 on day 2 every 2 weeks for 6 courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin IV 70 mgr/m2 on day 1 every 3 weeks for 4 courses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mgr/m2 on days 1 and 8 every 3 weeks for 4 courses
Study: NCT02190669

Intervention type: OTHER
Intervention: exercise
Description: Sprinting, walking on a treadmill, and stationary bicycle riding

Intervention type: OTHER
Intervention: exercise
Description: Sprinting, walking on a treadmill, and stationary bicycle riding

Intervention type: OTHER
Intervention: exercise
Description: Sprinting, walking on a treadmill, and stationary bicycle riding
Study: NCT02564939

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ramelteon
Description: double-blind RCT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: double-blind RCT
Study: NCT01066468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec/Glivec
Study: NCT01098136

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chiropractic
Description: Manual treatment of musculoskeletal complaints

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional medical intervention
Description: Medical, physiotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional and alternative intervention
Description: Medical and alternative methods for treatment of pelvic pain syndromes
Study: NCT02678416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Acetaminophen (Treatment A)
Description: Acetaminophen administered by intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Acetaminophen (Treatment B)
Description: Acetaminophen administered by oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Treatment C)
Description: Placebo administered by IV infusion or oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Treatment C)
Description: Placebo administered by IV infusion or oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Treatment C)
Description: Placebo administered by IV infusion or oral tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Treatment C)
Description: Placebo administered by IV infusion or oral tablets

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morphine (Treatment D)
Description: Morphine administered by IV infusion
Study: NCT01397864

Intervention type: DRUG
Intervention: rhC1INH or pdC1INH
Description: C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)
Study: NCT04696991

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The postpartum discharge education with PechaKucha Method.
Description: The postpartum discharge training in which the PechaKucha method was applied via the smartphones was offered to the mothers in the experimental group whereas the mothers in the control group had solely the routine discharge training. The postpartum training was offered as per the Postpartum Care Management Guideline of the Ministry of Health of Turkey. The discharge training was offered to the experimental group by using the PechaKucha presentation technique.
Study: NCT03500250

Intervention type: OTHER
Intervention: Post-Stroke Depression toolkit
Description: The Post-Stroke Depression toolkit consists of three components: (1) two screening instruments, (2) seven evidence-based nursing interventions, and (3) an instruction manual.
Study: NCT02257957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard care Hyaluronic acid eye drops
Description: : 15 patients with diagnosis of severe dry eye will receive standard of care treatment ( Hyaluronic acid eye drops 5 times per day). Objective measurements as corneal staining, Shirmer , BUT, and VA, will be determinate as subjective measurements as OSDI and treatment compliance will be evaluated at day 0-30,60 and 90
Study: NCT01938807

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CareCoach mobile application to assist in diabetes management

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CareCoach mobile application to assist in diabetes management
Study: NCT00356460

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Description: 1 dose of 0.1 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.1 mg/kg IV (one dose every 14 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Description: 1 dose of 0.3 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.3 mg/kg IV (one dose every 14 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Description: 1 dose of 1.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 1.0 mg/kg IV (one dose every 14 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Description: 1 dose of 3.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 3.0 mg/kg IV (one dose every 14 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Description: 1 dose of 10.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 10.0 mg/kg IV (one dose every 14 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Description: 1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody
Description: 1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody
Description: 1 dose of 15.0 or 10.0 mg/kg IV (based on safety profile of part 2, cohort 1) followed by a 28 day observation period and then 3 additional doses of 15.0 or 10.0 mg/kg IV (one dose every 14 days)
Study: NCT05208801

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Percutaneous injection
Description: A sham procedure of 2 ml of 1% lidocaine injected percutaneously using the initial 25G needle for local anesthetics

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Intrathecal injection of morphine 400mcg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine+Bupivacaine
Description: Intrathecal injection of 5mg of 0.5% bupivacaine chloride
Study: NCT02345122

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention: Mental Health Technician
Description: In addition to structured assessments at baseline, four, eight and twelve months (the results will be shared with their Primary Care Provider), subjects will receive psychoeducation regarding their depression, anxiety, and alcohol use disorder or at-risk drinking; symptom monitoring; and medication adherence support. Their Primary Care Provider will also be provided evidence-based recommendations regarding their treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Usual Care
Description: Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve months. The results will be shared with their Primary Care Provider.
Study: NCT02073734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 8mg/IV

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo given IV
Study: NCT02248220

Intervention type: DRUG
Intervention: Pramipexole
Study: NCT03598322

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 1mL injection
Description: Dextrose 1mL injection and hydrodissection for CTS

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dextrose 2mL injection
Description: Dextrose 2mL injection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dextrose 4mL injection
Description: Dextrose 4mL injection
Study: NCT00752622

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Description: Participants received Infliximab 5 mg/kg intravenously (IV) at weeks 0, 2 and 6 during the induction phase. At Week 10, those who were in clinical response received further treatment every 8 weeks during the observational phase

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Description: Participants received Infliximab 5 mg/kg intravenously (IV) at weeks 0, 2 and 6 during the induction phase. At Week 10, those who were in clinical response received further treatment every 8 weeks during the observational phase

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg every 6 weeks
Description: Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 5 mg/kg IV every 6 weeks (shortened interval group)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infliximab 7 mg/kg every 8 weeks
Description: Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 7 mg/kg IV every 8 weeks (increased dose group)
Study: NCT02141542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI3617
Study: NCT01023854

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous Paravertebral block
Description: The paravertébral block is a peripheral block which gets an one-sided continuous analgesia by infiltration of the spinal nerves which appear from the intervertebral foramen.~Its realization consists of a draining in 2-3 cm of the thorny apophyses ( T6-T8). During the perception of the osseous contact (cross-functional process of the vertebra), the needle is redirected in cephalic direction until a loss of resistance corresponding to the passage of the upper costo-cross-functional ligament that is in the entrance to the paravertébral space. A catheter is then inserted into the paravertébral space.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Continuous Paravertebral block
Description: The paravertébral block is a peripheral block which gets an one-sided continuous analgesia by infiltration of the spinal nerves which appear from the intervertebral foramen.~Its realization consists of a draining in 2-3 cm of the thorny apophyses ( T6-T8). During the perception of the osseous contact (cross-functional process of the vertebra), the needle is redirected in cephalic direction until a loss of resistance corresponding to the passage of the upper costo-cross-functional ligament that is in the entrance to the paravertébral space. A catheter is then inserted into the paravertébral space.